Showing results (41-50 of 277) with videos related to
Sort By:
Pageof 28
JCO Clinical Cancer Informatics|January 18, 2019
Reannotation and Analysis of Clinical and Chemotherapy Outcomes in the Ovarian Data Set From The Cancer Genome AtlasVictor M Villalobos, Yan C Wang, Branimir I SikicJournal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 4, 2008
Bronchioloalveolar carcinoma presenting as chronic progressive pulmonary infiltrates in a woman with HIV: a diagnosis worth makingTodd M Erickson, John R Koeppe, York E Miller, et al.International Journal of Radiation Oncology, Biology, Physics|June 9, 2019
Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation TherapyColton J Ladbury, Chad G Rusthoven, D Ross Camidge, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 2, 2019
Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLCD Ross Camidge, Elizabeth E Kim, Tiziana Usari, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 11, 2020
Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLCThomas E Stinchcombe, Robert C Doebele, Xiaofei Wang, et al.British Journal of Clinical Pharmacology|February 7, 2008
The impact of prognosis without treatment on doctors' and patients' resource allocation decisions and its relevance to new drug recommendation processesD Ross Camidge, James J Oliver, Carolyn Skinner, et al.Lung Cancer (Amsterdam, Netherlands)|December 12, 2018
Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitorTerry L Ng, Rustain L Morgan, Tejas Patil, et al.Acta Oncologica (Stockholm, Sweden)|April 18, 2009
Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysisKyle E Rusthoven, Susan F Hammerman, Brian D Kavanagh, et al.Journal of Medical Economics|September 1, 2021
Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancerCaitlin Smare, Kiran Dave, Ariadna Juarez-Garcia, et al.Clinical Lung Cancer|December 29, 2016
Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor TherapyDaniel J Becker, Juan P Wisnivesky, Michael L Grossbard, et al.Pageof 28